Hallucinogens like psilocybin activate serotonin 2A receptors (5-HT2AR) to produce psychoactive effects. Serotonin itself, the natural neurotransmitter, also activates these receptors but does not normally cause hallucinations. This study shows that serotonin triggers a specific signaling pathway involving β-arrestin2, phosphoinositide 3-kinase, Src, and Akt in the frontal cortex of mice, whereas N-methyltryptamines (hallucinogens) do not. In mice lacking β-arrestin2, serotonin-induced head-twitch responses (a behavioral proxy for receptor activation) were greatly reduced unless doses were elevated, and N-methyltryptamines produced stronger responses. Blocking N-methyltransferase prevented serotonin precursor-induced head twitches in knockout mice, suggesting N-methyltryptamines, not serotonin, mediate that response. This agonist-directed signaling bifurcation may inform drug development for conditions like schizophrenia or depression where hallucinations occur.
A new chemical synthesis method produces salvinorin analogs that are more potent, selective, stable, and functionally biased than the natural compound salvinorin A. These analogs target the kappa-opioid receptor and could serve as templates for next-generation pain relievers, anti-itch treatments, and dissociative hallucinogens. The synthesis uses a special organocatalyst and a cobalt-catalyzed cycloaddition to efficiently create a library of these complex molecules, overcoming previous difficulties in modifying their structure.
Salvinorin A (SalA) is a potent and selective kappa-opioid receptor agonist, but its chemical instability has hindered medicinal chemistry. Weak bases cause C8 epimerization, which destroys receptor affinity and signaling. Replacing C20 with hydrogen and O6 with CH2 stabilizes the scaffold so completely that epimerization is suppressed. The resulting compound, O6C-20-nor-SalA, retains high potency for kappa-opioid receptor agonism.
Deleting a single carbon atom (C20) from the complex plant metabolite salvinorin A stabilizes its molecular skeleton, simplifies its laboratory synthesis to just 10 steps, and preserves its high affinity and selectivity for the human kappa-opioid receptor. The work also introduces a general workflow for identifying structural changes that keep molecular complexity high while reducing synthetic complexity.